Otonomy Inc. fka OTIC

[Triple9]

$OTIC has a book value of $4.96 per share according to BarChart:

https://www.barchart.com/stocks/quotes/OTIC/profile

See the Company Profile page, and the box on the right with "OTIC Ratios".

While I've only ever heard of a handful of companies that closed operations and distributed cash to shareholders, this situation does mean that OTIC is undervalued as it's closing price yesterday was $3.35.

On OTIPRIO for Acute otitis externa, $OTIC had a successful Phase 3 in Jan of 2017. PDUFA date for sNDA filing is March 2, 2018.

So, in Q1 2018 IF OTIPRIO is approved, $OTIC should see a nice bump.

In the meantime, I'd expect OTIC to file for Phase 3 on OTO-311 for Tinnitus AND either refile an application for Ménière's disease (based on data review- was failure due to poor trial design?) or to purchase IP from another company and pursue a new pipeline.